Unió Europea - portuguès - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, tipo 2 - drogas usadas em diabetes - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Unió Europea - portuguès - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - agentes antitrombóticos - o possia, co-administrado com ácido acetilsalicílico (asa), é indicado para a prevenção de eventos aterotrombóticos em pacientes adultos com síndromes coronarianas agudas (angina instável, infarto do miocárdio sem elevação do st [nstemi] ou infarto do miocárdio com elevação do st [stemi] ); incluindo pacientes gerenciados medicamente, e aqueles que são administrados com intervenção coronária percutânea (pci) ou injerto de bypass da artéria coronária (cabg).

Unió Europea - portuguès - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - asma - medicamentos para obstrutiva, doenças das vias respiratórias, - fasenra é indicada como um complemento no tratamento de manutenção em pacientes adultos com graves eosinofílica asma inadequadamente controlada, apesar de altas doses de corticosteróides inalados mais longa ação de agonistas β.

Unió Europea - portuguès - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - doença pulmonar, obstrução crônica - formoterol e glycopyrronium brometo de - bevespi aerosphere é indicado como broncodilatador de manutenção de tratamento para aliviar os sintomas, em doentes adultos com doença pulmonar obstrutiva crônica (dpoc).

Unió Europea - portuguès - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - relacionados com drogas, efeitos colaterais e reações adversas - todos os outros produtos terapêuticos - para pacientes adultos tratados com uma diretos do fator xa (fxa) inibidor (apixaban ou o rivaroxaban) quando reversão da anticoagulação é necessária devido ao risco de vida ou sangramento descontrolado.

Unió Europea - portuguès - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - doença pulmonar, obstrução crônica - medicamentos para obstrutiva, doenças das vias respiratórias, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Unió Europea - portuguès - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucemia, linfocítica, crônica, células b - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Unió Europea - portuguès - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leucemia, células peludas - agentes antineoplásicos - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Unió Europea - portuguès - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplasias do peito - agentes antineoplásicos - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Unió Europea - portuguès - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vacinas - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. o uso desta vacina deve ser de acordo com as recomendações oficiais.